Key Developments: NeoStem Inc (NBS)
0.59USD
24 May 2013
$0.02 (+3.51%)
$0.57
$0.58
$0.59
$0.56
619,919
1,103,528
$0.84
$0.37
Latest Key Developments (Source: Significant Developments)
NeoStem Inc Announces Closing Of Public Offering Of Common Stock
NeoStem Inc announced the closing of a previously announced underwritten public offering of 23,000,000 shares of common stock, including the fully exercised over-allotment option by the underwriters covering 3,000,000 shares, offered at a price to the public of $0.50 per share. The gross proceeds to the Company were $11,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Aegis Capital Corp. acted as sole book-running manager of the offering. Full Article
NeoStem Inc Announces Pricing of Public Offering of Common Stock
NeoStem Inc announced the pricing of an underwritten public offering of 20,000,000 shares of common stock at a public offering price of $0.50 per share. The Company expects to receive $10,000,000 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters a 45-day option to purchase up to 3,000,000 additional shares of common stock to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, including AMR-001, expansion of business units, strategic transactions and other general corporate purposes. The financing is expected to close on or about May 3, 2013. Aegis Capital Corp. acted as sole book-running manager of the offering. Full Article
NeoStem Inc Announces Proposed Public Offering Of Common Stock
NeoStem Inc announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, including AMR-001, expansion of business units, strategic transactions and other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Full Article
NeoStem Inc's Progenitor Cell Therapy LLC Announces Services Agreement With Sentien Biotechnologies, Inc
NeoStem Inc and subsidiary, Progenitor Cell Therapy LLC (PCT) announced the execution of a Services Agreement with Sentien Biotechnologies, Inc. (Sentien) under which PCT will provide services to support Sentien's development of cell therapy product, including technology transfer, staff training, and manufacturing. Full Article
NeoStem Inc's Subsidiary, Progenitor Cell Therapy, And Hackensack University Medical Center Enter Into Cell Processing And Storage Services Agreement
NeoStem Inc and its subsidiary, Progenitor Cell Therapy, LLC (PCT), and Hackensack University Medical Center (HackensackUMC), part of the Hackensack University Health Network and a hub of healthcare for the Northern New Jersey and New York metropolitan areas, announced that HackensackUMC has renewed its engagement of PCT's services for processing and storage of a variety of cell types used therapeutically by the hospital. HackensackUMC will use the services of PCT for processing and storage services for peripheral blood progenitor cells, donor leukocytes, bone marrow and cord blood, as well as for further assays, storage, retrieval and transportation. Full Article
NeoStem Inc Announces New Publication That Supports Positive Results Of AMR-001 For Treatment Of Ami
NeoStem Inc announced a new article published by the International Scholarly Research Network provides further evidence that AMR-001, NeoStem's lead product candidate through its Amorcyte subsidiary, appears capable of preserving heart muscle function following a large myocardial infarction. Amorcyte demonstrated in its Phase 1 trial that AMR-001 preserved heart muscle function when a therapeutic dose of cells was administered. No patient experienced a deterioration in heart muscle function who received 10 million cells or more whereas 30 to 40% of patients not receiving a therapeutic dose did. The new study shows that cardiac muscle function sparing effects are evident even earlier after treatment than previously shown. AMR-001's angiogenic and anti-apoptotic mechanisms of action indicate that preservation of heart muscle function should start within weeks and be evident in fewer than 6 months. This publication, based on blinded analysis of Amorcyte's Phase 1 data, confirms the expected time course for AMR-001's mechanism of action. In the context of previously published results, these effects are durable. Amorcyte is developing AMR-001, a cell therapy for the treatment of cardiovascular disease, and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving cardiac function and preventing adverse clinical events after a large myocardial infarction. Full Article
Faruqi & Faruqi, LLP Launches Investigation Against NeoStem Inc
Faruqi & Faruqi, LLP, a national securities firm headquartered in New York City, is investigating the Board of Directors of NeoStem Inc (NeoStem or the Company) for potential breaches of fiduciary duties in connection with their conduct of seeking shareholders’ approval of the compensation for the Company’s named executive officers. The terms of the compensation to be awarded to the Company’s executive officers are outlined in the Proxy Statement on Form Schedule 14A that the Company filed with the Securities and Exchange Commission on September 7, 2012. Full Article
NeoStem Inc's Subsidiary And SOTIO, LLC Announces Phase 3 Manufacturing Services Agreement
NeoStem Inc announced that its subsidiary, Progenitor Cell Therapy, LLC (PCT), Contract Development and Manufacturing Organization (CDMO), and SOTIO, LLC, a Delaware limited liability company that is responsible for organizing the U.S. part of a global pivotal Phase 3 clinical trial of SOTIO, LLC's affiliate, SOTIO a.s. (SOTIO), announced that SOTIO, LLC has retained the services of PCT to manufacture clinical products for SOTIO's U.S. part of a global pivotal Phase 3 clinical trial. SOTIO, LLC will use the services of PCT to transfer and qualify at PCT's Allendale, New Jersey facility, SOTIO's GMP manufacturing process for the U.S. part of a global pivotal Phase 3 clinical trial for SOTIO's autologous dendritic cell vaccine expected to launch in early 2013, subject to FDA approval. As part of this agreement, PCT will complete a technology transfer of SOTIO's current product manufacturing and analytical procedures into PCT's ongoing CDMO operations. PCT will then implement and perform process qualification at the Allendale facility, and manufacture, store, and release the product for SOTIO's U.S. part of its global pivotal Phase 3 trial. The U.S. part of this double-blinded, randomized trial will enroll up to 250 patients and will be SOTIO's first trial in the U.S. Full Article
NeoStem Inc Closes Public Offering For $6,800,000 In Gross Proceeds
NeoStem Inc announced the closing of its previously announced underwritten public offering of 15,000,000 units and the exercise of the over-allotment option by the underwriter for an additional 2,000,000 units, bringing the total units offered to 17,000,000. The offering was priced at $0.40 per unit. Each unit consists of one share of common stock and a warrant to purchase one share of common stock with a per share exercise price of $0.51. Maxim Group LLC acted as sole book-running manager. Gross proceeds were $6,800,000, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. These funds will be used for working capital purposes, including research and development of cell therapeutic product candidates, expansion of business units, strategic transactions and other general corporate purposes. Full Article
NeoStem Inc Announces Pricing Of Public Offering For $6,000,000 In Gross Proceeds
NeoStem Inc announced the pricing of an underwritten public offering of 15,000,000 units at $0.40 per unit. Each unit consists of one share of common stock and a warrant to purchase one share of common stock with a per share exercise price of $0.51. Maxim Group LLC acted as sole bookrunner. The Company expects to receive $6,000,000 in gross proceeds, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. These funds will be used for working capital purposes, including research and development of cell therapeutic product candidates, expansion of business units, strategic transactions and other general corporate purposes. The Company has granted the underwriters a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments. The financing is expected to close on or about April 3, 2012. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
